Respiratory resources

 

SPIRIVA® Respimat® (tiotropium) is indicated as add-on maintenance bronchodilator treatment in patients aged 6 years and older with severe asthma who experienced one or more severe asthma exacerbations in the preceding year. SPIRIVA Respimat is indicated as a maintenance bronchodilator treatment to relieve symptoms of patients with chronic obstructive pulmonary disease (COPD)

SPIOLTO® Respimat (tiotropium & olodaterol) is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD.

Indications
Resource types
 
There are no results available at the moment based on the selection. Please reset the filters.

PC-GB-109610 V2

May 2024

Reporting adverse events

Adverse events should be reported. Reporting form and information can be found atwww.mhra.gov.uk/yellowcard. Adverse events should also be reported to Boehringer Ingelheim Drug Safety on0800 328 1627 (freephone).

Please be aware that this website contains promotional information about Boehringer Ingelheim medicines and services. Some of this may not be directly relevant to your scope of practice and it is your own decision whether you choose to view this information.